Clinical Trial Update: Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating dovitinib in combination with imatinib for gastrointestinal stromal tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Dovitinib (dovitinib)
• Imatinib (imatinib)

Snippet

Sponsor: Asan Medical Center | Conditions: Gastrointestinal Stromal Tumors | Phase 1 | Status: WITHDRAWN